PL1699459T3 - Sposób leczenia stwardnienia rozsianego - Google Patents
Sposób leczenia stwardnienia rozsianegoInfo
- Publication number
- PL1699459T3 PL1699459T3 PL04806691T PL04806691T PL1699459T3 PL 1699459 T3 PL1699459 T3 PL 1699459T3 PL 04806691 T PL04806691 T PL 04806691T PL 04806691 T PL04806691 T PL 04806691T PL 1699459 T3 PL1699459 T3 PL 1699459T3
- Authority
- PL
- Poland
- Prior art keywords
- multiple sclerosis
- meca
- treatment
- a3rag
- apnea
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 229940122614 Adenosine receptor agonist Drugs 0.000 abstract 3
- 239000003379 purinergic P1 receptor agonist Substances 0.000 abstract 3
- IPSYPUKKXMNCNQ-PFHKOEEOSA-N (2s,3s,4r,5r)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 IPSYPUKKXMNCNQ-PFHKOEEOSA-N 0.000 abstract 1
- LDYMCRRFCMRFKB-MOROJQBDSA-N (2s,3s,4r,5r)-5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=CC(N)=CC=3)=C2N=C1 LDYMCRRFCMRFKB-MOROJQBDSA-N 0.000 abstract 1
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 abstract 1
- 101150046889 ADORA3 gene Proteins 0.000 abstract 1
- 208000008784 apnea Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preliminary Treatment Of Fibers (AREA)
- Spinning Or Twisting Of Yarns (AREA)
- Steroid Compounds (AREA)
- Treatment Of Fiber Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Sewing Machines And Sewing (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53271203P | 2003-12-29 | 2003-12-29 | |
| PCT/IL2004/001160 WO2005063246A1 (en) | 2003-12-29 | 2004-12-23 | Method for treatment of multiple sclerosis |
| EP04806691A EP1699459B1 (en) | 2003-12-29 | 2004-12-23 | Method for treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1699459T3 true PL1699459T3 (pl) | 2007-12-31 |
Family
ID=34738826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04806691T PL1699459T3 (pl) | 2003-12-29 | 2004-12-23 | Sposób leczenia stwardnienia rozsianego |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7465715B2 (pl) |
| EP (1) | EP1699459B1 (pl) |
| JP (1) | JP2007517019A (pl) |
| CN (1) | CN100423723C (pl) |
| AT (1) | ATE363907T1 (pl) |
| DE (1) | DE602004006895T2 (pl) |
| DK (1) | DK1699459T3 (pl) |
| ES (1) | ES2287804T3 (pl) |
| PL (1) | PL1699459T3 (pl) |
| WO (1) | WO2005063246A1 (pl) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| AU2005310874B2 (en) | 2004-12-02 | 2008-11-27 | Can-Fite Biopharma Ltd. | Treatment of inflammation |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| EP1983990B1 (en) | 2006-01-26 | 2011-03-23 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | A3 adenosine receptor allosteric modulators |
| GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| ATE549337T1 (de) | 2006-04-21 | 2012-03-15 | Novartis Ag | Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten |
| GB0607950D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
| EP1903044A1 (en) | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| JP2010508835A (ja) * | 2006-11-10 | 2010-03-25 | ノバルティス アーゲー | シクロペンテンジオールモノアセテート誘導体 |
| US9102698B2 (en) | 2007-03-14 | 2015-08-11 | Can-Fite Biopharma Ltd. | Process for the synthesis of IB-MECA |
| US20090088403A1 (en) * | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
| US9199102B2 (en) | 2009-07-21 | 2015-12-01 | Oradin Pharmaceutical Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
| IL200753A (en) | 2009-09-06 | 2015-06-30 | Can Fite Biopharma Ltd | Pharmaceutical preparation containing ib – meca for the treatment of psoriasis |
| WO2012144512A1 (ja) * | 2011-04-22 | 2012-10-26 | 国立大学法人京都大学 | 関節リウマチの新規遺伝因子としてのミエリン塩基性蛋白の利用 |
| SG10201610936RA (en) | 2011-12-22 | 2017-02-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| JP2015504088A (ja) * | 2012-01-23 | 2015-02-05 | キャン−ファイト バイオファーマ リミテッドＣａｎ−Ｆｉｔｅ ＢｉｏＰｈａｒｍａ Ｌｔｄ． | 肝疾患の治療 |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2017185061A1 (en) | 2016-04-21 | 2017-10-26 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating neurological and cardiovascular conditions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| EP0708781B1 (en) * | 1993-07-13 | 2001-10-04 | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services | A 3 adenosine receptor agonists |
| WO1995011681A1 (en) | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
| WO1997033879A1 (en) * | 1996-03-15 | 1997-09-18 | Merck & Co., Inc. | Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor |
| YU44900A (sh) * | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| US6303619B1 (en) * | 1998-03-12 | 2001-10-16 | University Of Virginia | Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors |
| US7160890B2 (en) * | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| CZ294538B6 (cs) * | 2002-12-30 | 2005-01-12 | Ústav Experimentální Botaniky Akademie Vědčeské Re | Substituční deriváty N6-benzyladenosinu, způsob jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující |
-
2004
- 2004-12-23 EP EP04806691A patent/EP1699459B1/en not_active Expired - Lifetime
- 2004-12-23 AT AT04806691T patent/ATE363907T1/de not_active IP Right Cessation
- 2004-12-23 PL PL04806691T patent/PL1699459T3/pl unknown
- 2004-12-23 DK DK04806691T patent/DK1699459T3/da active
- 2004-12-23 ES ES04806691T patent/ES2287804T3/es not_active Expired - Lifetime
- 2004-12-23 DE DE602004006895T patent/DE602004006895T2/de not_active Expired - Fee Related
- 2004-12-23 JP JP2006546475A patent/JP2007517019A/ja not_active Withdrawn
- 2004-12-23 WO PCT/IL2004/001160 patent/WO2005063246A1/en not_active Ceased
- 2004-12-23 CN CNB2004800393344A patent/CN100423723C/zh not_active Expired - Fee Related
- 2004-12-23 US US10/521,193 patent/US7465715B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE363907T1 (de) | 2007-06-15 |
| DE602004006895D1 (de) | 2007-07-19 |
| JP2007517019A (ja) | 2007-06-28 |
| US20060142237A1 (en) | 2006-06-29 |
| ES2287804T3 (es) | 2007-12-16 |
| EP1699459A1 (en) | 2006-09-13 |
| WO2005063246A1 (en) | 2005-07-14 |
| CN1901915A (zh) | 2007-01-24 |
| CN100423723C (zh) | 2008-10-08 |
| DE602004006895T2 (de) | 2008-01-31 |
| EP1699459B1 (en) | 2007-06-06 |
| US7465715B2 (en) | 2008-12-16 |
| DK1699459T3 (da) | 2007-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1699459T3 (da) | Fremgangsmåde til behandling af multipel sclerose | |
| MY146986A (en) | Methods for treating interleukin-6 related diseases | |
| LU92323I2 (fr) | La combinaison de (a) dextromethorphan ou un de ses sels pharmaceutiquement acceptables, précursers ou dérivés, par ex. hydrobromure de dextromethorphan et en particulier hydrobromure de dextromethorphan monohydrate;et (b) quinidine ou un de ses selspharmacuetiquement acceptables, précurseurs ou dé rivés, par ex. sulfate de quinidine et en particulier sulfate de quinidine dihydrate | |
| AU2003296993A8 (en) | Cyclopropyl compounds as ccr5 antagonists | |
| WO2003063876A3 (en) | Methods of treating patients suffering from movement disorders | |
| WO2003064431A3 (en) | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them | |
| MXPA02001306A (es) | Composiciones farmaceuticas para el tratamiento de enfermedades del sistema nervioso central y otras enfermedades. | |
| EP1064966A3 (en) | Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine | |
| EP1213031A3 (en) | Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist | |
| WO2000053148A3 (en) | Methods and compositions for treating erectile dysfunction | |
| IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
| MXPA04002389A (es) | Combinacion de un antagonista del receptor de adenosian a2a y un antidepresivo o ansiolitico. | |
| WO2003072572A8 (en) | Beta3-adrenergic receptor agonists | |
| EP1387685A4 (en) | ANALGETIC COMPOSITION AND METHOD | |
| WO2003093503A3 (en) | Method for bioequivalence determination using expression profiling | |
| AU2204701A (en) | Formulations of adenosine a1 agonists | |
| TWI256388B (en) | Pharmaceutical combination | |
| WO2004029025A3 (en) | Methods and compositions for the treatment of autoimmune disorders using clofarabine | |
| PL376346A1 (pl) | Agoniści adrenoreceptora alfa 2B lub 2B/2C do leczenia neurodegeneracji | |
| WO2007006732A8 (en) | Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist) | |
| WO2003094957A3 (en) | Methods of therapy for inducing tolerance | |
| MX2007005525A (es) | Tratamiento terapeutico de resorcion ose acelerada. | |
| EP1064948A3 (en) | Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine | |
| NO20062883L (no) | Fosfodiesterase-V-inhibitorpreparater | |
| AU2203101A (en) | Formulations of adenosine a1 agonists |